• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Lexicon Pharmaceuticals, Inc. - Common Stock (NQ:LXRX)

    1.890 +1.890 (+1889900.00%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 11, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,041,413
    Open 0.0001
    Bid (Size) 1.920 (1,200)
    Ask (Size) 1.930 (10,000)
    Prev. Close 0.0001
    Today's Range 1.840 - 1.945
    52wk Range 0.6350 - 2.530
    Shares Outstanding 144,474,452
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026? ↗
    One company posts rapid revenue growth but remains unprofitable, while the other boasts global scale and steady cash flow. See how their fundamentals stack up. 
    Via The Motley Fool
    News headline image
    Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions
    Presentations highlight consistent A1c reductions with sotagliflozin in type 1 diabetes and pharmacokinetics of pilavapadin across renal function groups 
    From Lexicon Pharmaceuticals, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +65.8%
    +65.8%
    1 Month
    -21.6%
    -21.6%
    3 Month
    +9.9%
    +9.9%
    6 Month
    +43.2%
    +43.2%
    1 Year
    +169.2%
    +169.2%

    More News

    Read More
    News headline image
    Lexicon (LXRX) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    Lexicon Pharmaceuticals (NASDAQ:LXRX) Q1 2026 Results Show Revenue Beat and Narrowed Loss ↗
    Via Chartmill
    Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) Beats Q4 Estimates and Strengthens Cash Runway ↗
    Via Chartmill
    Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) Shows High-Growth Momentum with Strong Technical and Fundamental Trends ↗
    Via Chartmill
    News headline image
    Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
    From Lexicon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
    From Lexicon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Lexicon Pharmaceuticals Q1 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates
    From Lexicon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital
    From Lexicon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
    From Lexicon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting
    From Lexicon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo
    From Lexicon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851
    From Lexicon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes
    From Lexicon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Lexicon (LXRX) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates
    From Lexicon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences
    From Lexicon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026
    From Lexicon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
    From Lexicon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
    From Lexicon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Lexicon Announces Proposed Public Offering of Common Stock
    From Lexicon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary
    From Lexicon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain
    From Lexicon Pharmaceuticals, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Lexicon Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, Lexicon Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does Lexicon Pharmaceuticals, Inc. - Common Stock trade on?
    Lexicon Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Lexicon Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for Lexicon Pharmaceuticals, Inc. - Common Stock is LXRX on the Nasdaq Stock Market
    What is the current price of Lexicon Pharmaceuticals, Inc. - Common Stock?
    The current price of Lexicon Pharmaceuticals, Inc. - Common Stock is 1.890
    When was Lexicon Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of Lexicon Pharmaceuticals, Inc. - Common Stock was at 06/11/26 04:00 PM ET
    What is the market capitalization of Lexicon Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of Lexicon Pharmaceuticals, Inc. - Common Stock is 273.06M
    How many shares of Lexicon Pharmaceuticals, Inc. - Common Stock are outstanding?
    Lexicon Pharmaceuticals, Inc. - Common Stock has 273M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.